Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington’s disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington’s disease
Authors
Keywords
-
Journal
NEUROPSYCHOPHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-06-02
DOI
10.1038/s41386-018-0107-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)
- (2017) Carlotta Granchi et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease
- (2017) Sara Valdeolivas et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Endocannabinoid Actions on Cortical Terminals Orchestrate Local Modulation of Dopamine Release in the Nucleus Accumbens
- (2017) Yolanda Mateo et al. NEURON
- Endocannabinoid modulation of dopamine neurotransmission
- (2017) Dan P. Covey et al. NEUROPHARMACOLOGY
- Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling
- (2017) Gernot F. Grabner et al. PHARMACOLOGY & THERAPEUTICS
- Molecular Imaging Markers to Track Huntington’s Disease Pathology
- (2017) Heather Wilson et al. Frontiers in Neurology
- Longitudinal Psychiatric Symptoms in Prodromal Huntington’s Disease: A Decade of Data
- (2016) Eric A. Epping et al. AMERICAN JOURNAL OF PSYCHIATRY
- Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids
- (2016) Dan P. Covey et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
- (2016) Jose Luis López-Sendón Moreno et al. JOURNAL OF NEUROLOGY
- Phasic Dopamine Transmission Reflects Initiation Vigor and Exerted Effort in an Action- and Region-Specific Manner
- (2016) D. Ko et al. JOURNAL OF NEUROSCIENCE
- Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease
- (2016) Dan P. Covey et al. JOURNAL OF NEUROSCIENCE
- Inhibition of monoacylglycerol lipase reduces nicotine withdrawal
- (2015) P P Muldoon et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia
- (2015) Concepción García et al. BRITISH JOURNAL OF PHARMACOLOGY
- Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice
- (2015) Thomas F. Gamage et al. DRUG AND ALCOHOL DEPENDENCE
- Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior
- (2015) Samantha E Yohn et al. NEUROPSYCHOPHARMACOLOGY
- Cocaine-Induced Endocannabinoid Mobilization in the Ventral Tegmental Area
- (2015) Huikun Wang et al. Cell Reports
- Endocannabinoid-mediated retrograde modulation of synaptic transmission
- (2014) Takako Ohno-Shosaku et al. CURRENT OPINION IN NEUROBIOLOGY
- Apathy Is Not Depression in Huntington’s Disease
- (2014) Paul Naarding et al. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
- Current therapeutic options for Huntington's disease: Good clinical practice versus evidence-based approaches?
- (2014) Annie Killoran et al. MOVEMENT DISORDERS
- The VMAT-2 Inhibitor Tetrabenazine Affects Effort-Related Decision Making in a Progressive Ratio/Chow Feeding Choice Task: Reversal with Antidepressant Drugs
- (2014) Patrick A. Randall et al. PLoS One
- The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion
- (2014) Samantha E. Yohn et al. PSYCHOPHARMACOLOGY
- In Situ Electrode Calibration Strategy for Voltammetric Measurements In Vivo
- (2013) James G. Roberts et al. ANALYTICAL CHEMISTRY
- Cannabinoid Receptor Activation Shifts Temporally Engendered Patterns of Dopamine Release
- (2013) Erik B Oleson et al. NEUROPSYCHOPHARMACOLOGY
- Treatment of Huntington’s Disease
- (2013) Samuel Frank Neurotherapeutics
- Longitudinal Evaluation of Neuropsychiatric Symptoms in Huntington's Disease
- (2012) Jennifer C. Thompson et al. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
- Therapeutic potential of monoacylglycerol lipase inhibitors
- (2012) Melinda M. Mulvihill et al. LIFE SCIENCES
- Endocannabinoids Shape Accumbal Encoding of Cue-Motivated Behavior via CB1 Receptor Activation in the Ventral Tegmentum
- (2012) Erik B. Oleson et al. NEURON
- Comprehensive Behavioral and Molecular Characterization of a New Knock-In Mouse Model of Huntington’s Disease: zQ175
- (2012) Liliana B. Menalled et al. PLoS One
- Assessing Principal Component Regression Prediction of Neurochemicals Detected with Fast-Scan Cyclic Voltammetry
- (2011) Richard B. Keithley et al. ACS Chemical Neuroscience
- Demon Voltammetry and Analysis software: Analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures
- (2011) Jordan T. Yorgason et al. JOURNAL OF NEUROSCIENCE METHODS
- Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease
- (2010) Cristina Blázquez et al. BRAIN
- Cannabinoid-Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
- (2010) Javier Fernández-Ruiz et al. CNS Neuroscience & Therapeutics
- Chronic microsensors for longitudinal, subsecond dopamine detection in behaving animals
- (2009) Jeremy J Clark et al. NATURE METHODS
- Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease
- (2009) M.J. Dowie et al. NEUROSCIENCE
- The Endocannabinoid System in Huntingtons Disease
- (2008) M. Pazos et al. CURRENT PHARMACEUTICAL DESIGN
- Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
- (2008) Jonathan Z Long et al. Nature Chemical Biology
- Detection of Huntington's disease decades before diagnosis: the Predict-HD study
- (2007) J S Paulsen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels
- (2007) Zsuzsanna Sidló et al. NEUROCHEMISTRY INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search